Clinical trials: Migraine, With or Without Aura
Migraine, Migraine Headache
The Impact of Acupuncture on Biomarkers of Brain Injury and Inflammatory Response in Migraine
Migraine is more than just a headache-it can involve changes in the brain and inflammation. Recent research suggests that acupuncture may help by calming pain signals and reducing inflammation in the body.
- Conditions
- Migraine, Migraine Headache, Migraine Headache, With or Without Aura, Migraine in Adults
- Trial name
- ACUPMIGRAINE (NCT07292506)
- Testing
- Standard acupuncture, Electroacupuncture, Laser Acupuncture
- Where
- Slovenia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Migraine, With or Without Aura
Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults
The purpose of this study is to evaluate the long-term safety of BR005-036C tablets in the acute treatment of migraines
- Trial name
- NCT07835152
- Testing
- BR005-036C
- Where
- 81 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.
Migraine
Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines.
- Trial name
- NCT00122278
- Testing
- Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 205 people
- Sponsor
- Montefiore Medical Center
Migraine With Aura, Migraine Without Aura
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.
- Trial name
- NCT00123201
- Testing
- Dronabinol MDI
- Where
- 29 sites in United States
- Sponsor
- Solvay Pharmaceuticals
Migraine
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
The main purpose of this study is to evaluate the longer term safety of the study drug known as galcanezumab in participants with episodic or chronic migraine.
- Trial name
- NCT02614287
- Testing
- Galcanezumab
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 270 people
- Sponsor
- Eli Lilly and Company
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine
Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches
Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.
- Trial name
- NCT02472418
- Testing
- DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B)
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine
Study of EVO756 in Adults With Migraine
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
- Trial name
- NCT07616128
- Testing
- EVO756, Dose 1, EVO756, Dose 2
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 330 people
- Sponsor
- Evommune, Inc.
Migraine Disorders
Migraine Study in Adolescent Patients
This study was designed to determine how well the combination medication, sumatriptan and naproxen sodium, treats migraine headache in adolescents 12-17 years old
- Trial name
- NCT00843024
- Testing
- Sumatriptan and Naproxen Sodium
- Where
- 79 sites in United States
- Volunteers
- 589 people
- Sponsor
- GlaxoSmithKline
Headache Disorders, Primary, Migraine With Aura
IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headaches are a common medical problem that physicians frequently encounter in their practice. One of key findings of The Atlas of Headache Disorders prepared by World Health Organization (WHO) is: headache disorders, including…
- Conditions
- Headache Disorders, Primary, Migraine With Aura, Migraine Without Aura, Tension-Type Headache
- Trial name
- PRESTO (NCT02115269)
- Where
- 30 sites in Kazakhstan, Ukraine
- Volunteers
- 759 people
- Sponsor
- Abbott
Ischemic Stroke, Migraine
Sensitivity to Acute Cerebral Ischemia in Migrainers
Sensitivity to Acute Middle cerebral or intracranial Carotid artery Occlusion in MIGrainers (SMCO-MIG) is a prospective multi-center study to determine if migraine induces a faster infarct growth as assessed by initial multimodal…
- Conditions
- Ischemic Stroke, Migraine, Migraine With Aura
- Trial name
- SAMCO-MIG (NCT03301441)
- Testing
- questionnaire ef-ID Migraine
- Where
- France
- Volunteers
- 605 people
- Sponsor
- University Hospital, Montpellier
Migraine, Migraine Disease
A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with…
- Conditions
- Migraine, Migraine Disease, Migraine in Adults, Migraine Headache
- Trial name
- NCT07667621
- Testing
- Rimegepant, Zavegepant
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Migraine With or Without Aura
The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination
The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders
- Trial name
- NCT03194555
- Testing
- Low-Dose Naltrexone and Acetaminophen Combination
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine, Migraine Disease
Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
Caffeine extracted from green tea to abort acute attack of Migraine
- Conditions
- Migraine, Migraine Disease, Migraine Headache, Migraine Headache, With or Without Aura
- Trial name
- NCT07022496
- Testing
- Caffeine (200 mg), triptans, NSAID (Nonsteroidal anti-inflammatory drugs)
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Migraine Headache
Efficacy, Tolerability, and Safety of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States
- Trial name
- NCT03009019
- Testing
- DFN-15 Active
- Where
- 43 sites in United States
- Volunteers
- 631 people
- Sponsor
- BioDelivery Sciences International
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Migraine With or Without Aura
An Acute Migraine Factorial Study
The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
- Trial name
- ANODYNE-1 (NCT06245902)
- Testing
- Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine With or Without Aura
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study
A previously published, placebo-controlled, head-to-head comparator study found eletriptan to have superior efficacy to oral sumatriptan 100 mg in treating a single acute migraine attack.
- Trial name
- NCT01986088
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg, Sumatriptan 50 mg
- Volunteers
- 1,008 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine, With or Without Aura
Safety and Efficacy Study in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03235479
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,485 people
- Sponsor
- Pfizer